The Global Health Body Sounds Concern Over Acute Shortage of Obesity Injections

Under one in 10 individuals who could benefit from GLP-1 drugs such as Wegovy are able to get them, caution the global health agency as it releases its initial advice on the medications.

With in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is urging more widespread and fairer availability to this class of drugs.

According to forecasts, more than two billion are projected to be obese by 2030 without intervention.

"Our latest guidelines affirms that obesity is a chronic disease that can be treated with holistic and ongoing support," remarked its chief Tedros Adhanom Ghebreyesus.

Substantial prices, constrained manufacturing, and distribution challenges are significant barriers to universal access to the injections that can aid individuals in losing substantial weight, explains the body.

GLP-1 Therapy Supply Crisis

Even in the current most favorable outlook, the production of GLP-1 therapies might only reach around 100 million people – fewer than 10% of the global need, as stated by the health organization.

The advice encourages governments and firms to widen availability, through measures including voluntary licensing.

The intellectual property rights on a key compound – the main ingredient of a leading brand – is scheduled to end in several nations in 2026.

The Way Weight-Loss Jabs Work

These medications replicate a biological compound to delay gastric emptying, reduce hunger and increase feelings of fullness so people consume fewer calories.

People commonly see weight reduction in the initial weeks of starting on the weekly injections.

Evidence indicates users may put most of the weight back on within a year of halting the drug, as their normal hunger return.

To be overweight or obese raises your risk for contracting diseases, including type 2 diabetes, heart disease, stroke, and certain malignancies.

Obesity concerns individuals in all nations and was linked to millions of deaths worldwide in 2024, according to the WHO.